fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ISH/BSH 2016: Professor John Radford (The University of Manchester) and Dr Graham Collins (Oxford University Hospitals) discuss the key issues to come out of the session on challenging current clinical practices in HL. Also included associated article entitled 'Rethinking risk for better outcomes in ASCT'

Written by | 7 Jun 2016

Rethinking risk for better outcomes in ASCT by Christine Clark Dr Craig Moskowitz, Memorial Sloan Kettering Cancer Center, NY, USA. Patient populations are changing – before 2010 all… read more.

ISH/BSH 2016: Professor Philippe Moreau from Nantes in France reviewed the rationale for the new diagnostic criteria and highlighted the gaps in current risk models for stratifying the risk of progression to MM… Also included article entitled ‘High-risk smouldering myeloma’

Written by | 2 Jun 2016

High-risk smouldering myeloma by Maria Dalby Professor Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Subsequent to the publication of updated diagnostic criteria for MM in 2014,1 MM clinicians have… read more.

ISH/BSH 2016: Advances in our understanding of clonal evolution in MM: where are we now?

Written by | 2 Jun 2016

Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA. by Maria Dalby: The dramatic improvement in MM survival in the last 40 years is largely linked to the introduction… read more.

World Health Matters: Italy – 3D screening detects more cancers in dense breast tissue

Written by | 25 May 2016

by Gary Finnegan: Researchers have found that in over 3,000 Italian women with dense breasts where standard mammograms had not detected any cancer, the addition of tomosynthesis (a… read more.

For grade 2 glioma, radiation plus chemo betters radiation alone

Written by | 26 Apr 2016

by Bruce Sylvester: Patients with grade 2 glioma who received radiation therapy plus PCV chemotherapy (procarbazine, lomustine and vincristine) have achieved longer progression-free survival and overall survival than… read more.

World Health Matters: Italy: Leukaemia death rate expected to fall in 2016

Written by | 22 Feb 2016

by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.

ASH 2015: We ask Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) what the role of PET/CT is as a measure of MRD post ASCT and ask Professor Antonio Palumbo (University of Torino, Italy) and Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) whether MRD measurement is ready for clinical use

Written by | 10 Feb 2016

Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.

ASH 2015: Risk profile key in transplant decisions in non-Hodgkin lymphoma

Written by | 18 Jan 2016

by Thomas R. Collins: There could be a role for consolidation autologous stem cell transplantation for patients with diffuse, aggressive non-Hodgkin lymphomas (NHL) who are at high risk… read more.

ASH 2015: Trials exploring new settings for monoclonal antibodies in MM

Written by | 12 Jan 2016

by Thomas R. Collins: Trials are continuing to explore potential new settings for daratumumab and elotuzumab, two monoclonal antibodies that were recently approved for use in multiple myeloma… read more.

Resection safe and helpful for high-risk, early-stage lung cancer patients

Written by | 11 Dec 2015

by Bruce Sylvester: Surgical resection is a safe and helpful treatment option for a broad range of patients with early-stage lung cancer, researchers reported online on  Nov. 10,… read more.

Androgen deprivation therapy problematic for prior heart attack victims

Written by | 23 Oct 2015

by Bruce Sylvester: Men who have had a heart attack and then receive androgen deprivation therapy (ADT) for prostate cancer are at an increased risk of subsequent fatal… read more.

World Health Matters: Exercise helps women tolerate chemotherapy

Written by | 19 Oct 2015

by Gary Finnegan: Netherlands: Women with breast cancer who follow a physical exercise programme during their chemotherapy treatment experience fewer side effects, according a study by the Netherlands… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.